A61K 39/20
Rubella virus
A61K39/20 (Rubella virus) appears on 22 US grants and 25 published applications in this corpus.
Search patents in A61K- Granted patents
- 22
- Published applications
- 25
- Assignees
- 29
- Inventors
- 82
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 3 |
| 2015 | 0 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 2 |
| 2018 | 1 | 2 |
| 2019 | 2 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 0 |
| 2023 | 2 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 4 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Compositions and methods for stabilization of active agents22 Apr 2025US 12,280,101 B2Trustees of Tufts College
- Rubella virus spike construct10 Oct 2023US 11,780,884 B2Institut Virion \ Serion GmbH
- Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response22 Aug 2023US 11,730,810 B2Children's Medical Center Corporation
- Methods and compositions for therapeutic agents9 Nov 2021US 11,167,032 B2Variation Biotechnologies Inc.
- Vaccine antigens and use thereof29 Jan 2026US 2026/0027197 A1Morehouse School of Medicine
- Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen30 Oct 2025US 2025/0332250 A1SK Bioscience Co., Ltd.
- Methods and Microneedle Devices for Vaccinations with Enhanced Delivery and Acceptance23 Oct 2025US 2025/0325286 A1Micron Biomedical, Inc.
- Signal sequences for nucleic acid vaccines22 May 2025US 2025/0161425 A1Sanofi
- Freeze-dried viral combination vaccine compositions and process for preparation thereof20 Feb 2025US 2025/0057939 A1Codagenix Inc.
Most cited
By later US patents
- Materials and methods for treatment of plaquing diseases96US 5,851,996 AMilkhaus Laboratory, Inc. · 1998
- Materials and methods for treatment of plaquing disease92US 5,753,624 AMilkhaus Laboratory, Inc. · 1998
- Transcutaneous delivery of therapeutic agents49US 8,728,491 B2Alba Therapeutics Corporation · 2014
- Production of viruses in tissue culture without use of serum39US 4,072,565 AThe Dow Chemical Company · 1978
- Stabilizers for live vaccines25US 6,231,860 B1Pasteur Merieux Serums & Vaccins · 2001